According to SIGA Technologies's latest financial reports the company's current revenue (TTM) is $0.13 B. In 2022 the company made a revenue of $0.11 B a decrease over the years 2021 revenue that were of $0.13 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.13 B | 26.31% |
2022 | $0.11 B | -17.13% |
2021 | $0.13 B | 6.97% |
2020 | $0.12 B | 367.28% |
2019 | $26.74 M | -94.39% |
2018 | $0.47 B | 3788.3% |
2017 | $12.26 M | -18.14% |
2016 | $14.98 M | 83.32% |
2015 | $8.17 M | 160.39% |
2014 | $3.13 M | -43.11% |
2013 | $5.51 M | -38.48% |
2012 | $8.97 M | -29.51% |
2011 | $12.72 M | -33.77% |
2010 | $19.21 M | 39.13% |
2009 | $13.81 M | 71.24% |
2008 | $8.06 M | 20.41% |
2007 | $6.69 M | -7.7% |
2006 | $7.25 M | -14.38% |
2005 | $8.47 M | 360.9% |
2004 | $1.83 M | 151.34% |
2003 | $0.73 M | |
2001 | $1.15 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Sarepta Therapeutics
SRPT | $1.24 B | 788.62% | ๐บ๐ธ USA |
Novavax NVAX | $0.69 B | 395.62% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $6.88 M | -95.08% | ๐บ๐ธ USA |
NanoViricides NNVC | N/A | N/A | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $0.33 B | 136.86% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $1.02 B | 631.72% | ๐บ๐ธ USA |